Business context and reporting period
The supplied filing is AzurRx BioPharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed March 30, 2020. This does not match the request metadata naming Gridai Technologies Corp. or describing the period as 2019 Q4. The filing reports full-year results, not standalone fourth-quarter results.
AzurRx is a clinical-stage biopharmaceutical company developing non-systemic biologics for gastrointestinal disorders. Its lead candidate, MS1819, is in development for exocrine pancreatic insufficiency associated with cystic fibrosis (CF) and chronic pancreatitis (CP). It has no approved products and has never generated product-sales revenue.
Financial results and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.68 million | $5.77 million |
| General and administrative expense | $6.06 million | $7.45 million |
| Interest expense | $434,000 | $102,000 |
| Net loss | $15.18 million | $13.53 million |
| Basic and diluted loss per share | $0.68 | $0.88 |
| Net cash used in operating activities | $14.03 million | $10.87 million |
Gross and operating margins are not meaningful because the company reported no revenue. Research and development spending rose about 50%, primarily due to clinical-trial costs; reported G&A expense fell about 19%, although cash G&A spending increased about 23%, including a $367,908 cyber-fraud loss.
At year-end, cash and cash equivalents were $175,796, current assets were $3.41 million, and current liabilities were $4.29 million, producing negative working capital of approximately $877,000. Other receivables totaled $2.64 million, primarily French research tax credits; the company reported receiving approximately $1.13 million of its 2018 credit in February 2020. Total assets were $8.90 million. The balance sheet showed $1.08 million of convertible debt net of discounts and $444,364 of insurance-financing notes payable; the company also had accounts payable and accrued expenses, including related-party amounts.
Operating cash use exceeded 2019 financing cash inflows of $13.14 million, principally from public stock offerings and convertible debt. Cash declined from $1.11 million at the end of 2018. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. No dividend was paid or planned.
Material changes versus 2018
- Net loss increased by $1.64 million, while operating cash use increased by approximately $3.16 million.
- R&D expense increased by $2.91 million as clinical development advanced; G&A expense declined, partly reflecting lower noncash compensation.
- Common shares outstanding increased from 17.70 million to 26.80 million. The company raised equity in three 2019 offerings and entered a $15 million equity purchase facility, which can result in further dilution.
- In March 2019, the company acquired the remaining MS1819 rights from Mayoly, recording $3.80 million in patent assets and taking on specified payment obligations. It received worldwide MS1819 rights except for France and Russia, where Mayoly retained royalty-bearing rights.
Outlook, risks, contingencies, and unusual items
- Clinical outlook: The CP Phase 2a study reported a 21.8% mean CFA improvement at the highest dose in a preplanned per-protocol analysis (11 patients; p=0.002). In the 32-completer CF OPTION crossover study, about half reached CFA non-inferiority versus standard porcine enzyme replacement therapy; the study was not powered for statistical significance. Nitrogen absorption was reported as 93% for MS1819 versus 97% for PERT. The safety monitoring board reported no safety concerns.
- Planned trials: Management anticipated an FDA response on the OPTION 2 protocol in March 2020 and a possible trial start in Q2 2020, subject to regulatory approval. The Combination Trial planned to enroll about 24 patients. Management cautioned that COVID-19 could delay recruitment, trial conduct, and completion; these were expectations, not assurances.
- Funding and debt: A December 2019–January 2020 offering raised $6.904 million in principal of 9% senior convertible notes, convertible at $0.97 per share, with warrants exercisable at $1.07. The notes mature September 20, 2020. The company reported approximately $6.23 million in net proceeds from the offering. It repaid the remaining $450,000 ADEC note principal plus accrued interest in January 2020. Management expected to seek further financing and noted possible debt restructuring or extension. Failure to raise funds could constrain operations and development.
- COVID-19 and listing: The company said the pandemic’s duration and financial impact could not be reasonably estimated and anticipated needing additional financing. Nasdaq notified it in March 2020 that its share price failed the $1.00 minimum bid requirement; the initial compliance period ran through September 21, 2020, with possible extension subject to conditions.
- Unusual loss and controls: A cyber-related vendor-impersonation fraud redirected $418,765; $50,858 had been recovered, leaving a recorded $367,908 loss. The company added payment-verification controls and cybersecurity training. Management reported disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal control.
- Other contingencies: Former CEO Johan Spoor challenged the company’s decision not to pay an accrued $255,000 bonus; the filing also describes negotiations concerning related-party payables and 241,667 earned but unissued restricted shares. No material legal proceedings were reported. The company approved a potential 1-for-2 to 1-for-5 reverse split, but had not effected one by year-end.
Most important facts an investor should verify
- Confirm the issuer and filing period: the provided filing is AzurRx BioPharma’s 2019 Form 10-K, not a Gridai Technologies Corp. filing or a quarterly report.
- Review audited statements and subsequent-event disclosures for cash runway, the going-concern uncertainty, and the timing and terms of additional financing.
- Verify the notes’ outstanding principal, maturity, interest, conversion and warrant terms, and the extent of potential share dilution; distinguish the year-end balance-sheet carrying amount from gross notes issued through January 2020.
- Check FDA actions and actual enrollment, timing, and results for OPTION 2 and the Combination Trial, including COVID-19-related changes.
- Assess the recoverability and timing of French tax credits and the status of recovery efforts for the cyber-fraud loss.
- Check Nasdaq bid-price compliance and any reverse-split action, as well as the status of the former CEO compensation and share claims.